Common experiences during weeks 1-2 include mild nausea (reported by approximately 14% of participants at the 1 mg dose level), slight changes in appetite timing, increased awareness of fullness cues, and occasional fatigue as the body processes a new metabolic signal
Thus, many Americans have been exposed to the big names of GLP-1 drugs like Ozempic, Wegovy and Zepbound
Generic semaglutide remains 5 to 7+ years away based on patent timelines
Here, we primarily discuss GLP-1RAs that are currently approved and under consideration for MASLD, along with some co-agonist strategies showing promising results
But I wanted to see how the process felt from a patients perspective
Clinical data indicate actual changes in several areas of metabolic health